Study: CBD Improves Frequency and Severity of Seizures and Reduces Adverse Events

The use of cannabidiol (CBD) “improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study” published by the journal Epilepsy and Behavior.

The objective of this study “was to characterize the changes in adverse events, seizure severity, and frequency in response to a pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex®) in a large, prospective, single-center, open-label study.”

Researchers initiated CBD in 72 children and 60 adults with treatment-resistant epilepsy (TRE) at 5 mg/kg/day and titrated it up to a maximum dosage of 50 mg/kg/day. At each visit, researchers “monitored treatment adverse events with the adverse events profile (AEP), seizure severity using the Chalfont Seizure Severity Scale (CSSS), and seizure frequency (SF) using seizure calendars.” They “analyzed data for the enrollment and visits at 12, 24, and 48 weeks”, and “recorded AEP, CSSS, and SF at each follow-up visit for the weeks preceding the visit (seizures were averaged over 2-week periods).”

Of the 139 study participants in this ongoing study, at the time of analysis, 132 had 12-week, 88 had 24-week, and 61 had 48-week data. Study retention was 77% at one year. There were no significant differences between participants who contributed all 4 data points

Read More Here...

Leave a Reply

Your email address will not be published. Required fields are marked *